Safety and biological efficacy of an adeno-Associated virus vector-Cystic fibrosis transmembrane regulator (aav-Cftr) in the cystic fibrosis maxillary sinus

Laryngoscope

Volumn 109, Issue 2, 1999, Pages 266-274

  Wagner, John A ^a   Messner, Anna H ^a   Moran, Mary Lynn ^a   Daifuku, Richard ^b   Kouyama, Keisuke ^a   Desch, Julie K ^c   Manley, Sara ^b   Norbash, Alexander M ^a   Conrad, Carol K ^a   Friborg, Sandra ^b   Reynolds, Thomas ^b   Guggino, William B ^d   Moss, Richard B ^a   Carter, Barrie J ^b   Wine, Jeffrey J ^a   Flotte, Terence R ^e   Gardner, Phyllis ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Targeted Genetics Corporation   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CHLORIDE; COMPLEMENTARY DNA; ISOPRENALINE; SODIUM CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; EPITHELIUM CELL; FEMALE; GENE DOSAGE; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; MAXILLARY SINUS; MEMBRANE POTENTIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY EPITHELIUM; SAFETY; TREATMENT OUTCOME;

ADULT; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; MAXILLARY SINUSITIS; PARVOVIRIDAE INFECTIONS; POINT MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAFETY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0033022349     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1097/00005537-199902000-00017     Document Type: Article

References (19)

1. Wagner JA, Gardner P. Toward cystic fibrosis gene therapy. Annu Rev Med 1997;48:203-16.
2. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
3. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995;6:1487-96.
4. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333:823-31.
5. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-16.
6. Zabner J, Ramsey BW, Meeker DP, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504-11.
7. Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39-46.
8. Gill DR, Southern KW, KA M, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:199-209.
9. Porteous DJ, JR D, G M, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:210-8.
10. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237-45.
11. Flotte TR, Afione SA, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993;90:10613-7.
12. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994;11:517-21.
13. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996;3:658-68.
14. Moss RB, King VV. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage: reduction in recurrence requiring surgery. Arch Otolaryngol Head Neck Surg 1995;121:566-72.
15. Wine JJ, King VV, Lewiston NJ. Method for rapid evaluation of topically applied agents to cystic fibrosis airways. Am J Physiol 1991;261:L218-21.
16. Wagner JA, Moran ML, Messner AH. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 1998;9:889-909.
17. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996;70:3235-41.
18. Riddell SR, Elliot M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-23.
19. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-5.